BPC-157 + TB-500: dosing evidence
Human schedule
Controlled data on this compound are limited. The regimens below were gathered from public sources online (studies and protocols) and are given as a reference, not a usage plan.
Both peptides are typically given subcutaneously (SubQ); BPC-157 is often placed nearer the area of interest, while TB-500 acts systemically from any site. The figures below are a generalized reference drawn from research and clinic protocols, not a single standard.
This is a concise reference to regimens described for adults; it is not an individual prescription.
| Period / condition | Dose | Escalation |
|---|---|---|
| Loading phase (weeks 1-4) | BPC-157 250-500 mcg/day SubQ + TB-500 2-2.5 mg twice weekly | Starting dose |
| Maintenance phase (weeks 5-8) | BPC-157 250 mcg/day + TB-500 2 mg weekly | Maximum in this schedule |
| Course length | 4-8 weeks (up to 12 for chronic cases) | , |